Brief: Mineralys Therapeutics Announces Presentation Of New Data From The Late-Stage Launch-Htn Trial Of Lorundrostat
18/05/2026 21:06
May 18 (Reuters) - Mineralys Therapeutics Inc MLYS.O: MINERALYS THERAPEUTICS ANNOUNCES PRESENTATION OF NEW DATA FROM THE PHASE 3 LAUNCH-HTN TRIAL OF LORUNDROSTAT AT THE 35TH EUROPEAN MEETING ON HYPERTENSION AND CARDIOVASCULAR PROTECTION (ESH 2026) Source text: ID:nGNXc1pWLW Further company coverage: MLYS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway